Results about: innovation
ICREA researcher and group leader of the Stem Cells and Cancer Laboratory at IRB Barcelona receives an award for his work on cancer.
The prize acknowledges Salvador Aznar Benitah's contributions to transferring knowledge from basic to clinical research.
Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.
A study at IRB Barcelona has identified the cells responsible for initiating and promoting metastasis in several types of human tumours.
Their results show that the protein CD36, which absorbs fat from the cell membrane, is an essential factor that determines whether tumour cells become metastatic.
In the absence of CD36, the human tumours analysed did not develop metastasis. In addition, the inhibition of this protein also dramatically reduced the size of existing metastases.
Mice given a high-fat diet developed the most aggressive metastases. The study reports that the metastatic process is enhanced by fat intake.
IRB Barcelona will co-develop antibodies against CD36 with the potential to treat patients.
He is awarded this prize for his work on colon cancer
This prestigious prize is given in recognition of molecular biology research performed by scientists working in Spain
IRB Barcelona fosters entrepreneurship among its young scientists. Two postdoctoral fellows tell in vivo about their experience of learning how to deal with markets, patents and venture capitalists.
The Bilbao Exhibition Center (BEC) in Barakaldo (Vizcaya) is the venue of BioSpain 2016, the eighth of these biennial biotech gatherings, the most important event in this sector in Europe and permanently held in Spain, and fifth-ranked event worldwide for the number of partnering meetings held.
Nostrum BioDiscovery has come about from the combined efforts of IRB Barcelona and the BSC-CNS—two research centres of excellence in Barcelona—with the participation of the University of Barcelona and ICREA and supported by the Botín Foundation’s technology transfer programme.
The company boasts cutting-edge bioinformatics technologies to speed up the development and lower the cost of designing drugs—which are becoming increasingly more complex and expensive—and to further precision medicine.